Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 120.87% | 187.50% | 145.92% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.35% | 81.46% | 85.84% | -- | -- |
| Operating Income | -55.35% | -81.46% | -85.84% | -- | -- |
| Income Before Tax | -48.88% | -69.21% | -75.46% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.88% | -69.21% | -75.46% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.88% | -69.21% | -75.46% | -- | -- |
| EBIT | -55.35% | -81.46% | -85.84% | -- | -- |
| EBITDA | -55.40% | -81.93% | -86.49% | -- | -- |
| EPS Basic | 72.42% | 73.79% | 43.93% | -- | -- |
| Normalized Basic EPS | 72.72% | 73.78% | 43.93% | -- | -- |
| EPS Diluted | 72.42% | 73.79% | 43.93% | -- | -- |
| Normalized Diluted EPS | 72.72% | 73.78% | 43.93% | -- | -- |
| Average Basic Shares Outstanding | 273.54% | 558.40% | 407.89% | -- | -- |
| Average Diluted Shares Outstanding | 273.54% | 558.40% | 407.89% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |